Current and emerging treatment options for myopic choroidal neovascularization
Authors:
Open Access
- 1 April 2015
- journal article
- review article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 9, 733-744
Abstract
Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger than 50 years of age. There are different treatments for myopic CNV (mCNV), with 5- to 10-year outcomes currently. Chorioretinal atrophy is still the most important determinant factor for visual outcome. The purpose of this study is to provide an overview of the current treatments for mCNV, including laser, surgical management, verteporfin photodynamic therapy, and mainly anti-vascular endothelial growth factor therapy. Emerging treatment options are also discussed.Keywords
This publication has 80 references indexed in Scilit:
- Sustained release of avastin® from polysaccharides cross-linked hydrogels for ocular drug deliveryInternational Journal of Biological Macromolecules, 2013
- INTRAVITREAL PEGAPTANIB SODIUM (MACUGEN) FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2013
- Genetic Factors for Choroidal Neovascularization Associated with High MyopiaInvestigative Ophthalmology & Visual Science, 2012
- Sphingosine‐1‐phosphate antibodies as potential agents in the treatment of cancer and age‐related macular degenerationBritish Journal of Pharmacology, 2011
- Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular DegenerationMolecular Therapy, 2011
- Genome-Wide Association Studies Reveal Genetic Variants in CTNND2 for High Myopia in Singapore ChineseOphthalmology, 2011
- Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularizationEye, 2011
- Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic InjuryThe American Journal of Pathology, 2007
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBritish Journal of Ophthalmology, 2007